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STAT3 as a Biomarker of Progression in Atypical Nevi
of Patients with Melanoma: Dose–Response Effects of
Systemic IFNa Therapy
Wenjun Wang1, Howard D. Edington2, Uma N.M. Rao3, Drazen M. Jukic3,4, Hong Wang5,
Janice M. Shipe-Spotloe1 and John M. Kirkwood1
Signal transducer and activator of transcription (STAT3) plays a pivotal role in tumor progression. Atypical nevi
are nonobligate risk markers of melanoma, affording investigators a target for evaluation of progression
biomarkers in vivo. pSTAT1tyr701 (pSTAT1) and pSTAT3tyr705 (pSTAT3) oppose one another in biological
function. Therefore, an analysis of phosphorylated STAT1 (pSTAT1) and pSTAT3 signaling was performed
simultaneously using double-immunohistochemistry in biopsies of 168 atypical nevi from 42 patients receiving
high- or low-dose IFNa (HDI and LDI). With maturation of melanocytes from junctional into dermal
components of nevi, pSTAT1 expression increased, whereas pSTAT3 expression decreased. The percentage of
pSTAT3-positive melanocytes was positively associated with the atypical degree of nevi (Po0.0001). In the
junctional component of nevomelanocytic lesions, HDI and LDI downregulated the percentage of pSTAT3-
positive melanocytes (P¼ 0.008 and P¼ 0.0003, respectively) while upregulating the percentage of pSTAT1-
positive melanocytes (P¼ 0.016 and P¼ 0.0059, respectively) and augmented the pSTAT1/pSTAT3 ratio (P¼ 0.008
and P¼ 0.0040, respectively). It is suggested that the relative balance of pSTAT1/pSTAT3 may be associated with
melanocyte differentiation in vivo. pSTAT3 is a potential biomarker of melanocytic transformation and
progression and is modulated by IFNa dose-dependently. STAT3 is a potential target for chemoprevention of
melanoma.
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INTRODUCTION
Melanoma incidence is rising at a rate exceeding that of all
other solid tumors, and to date, no therapy has shown a
significant impact on the overall survival of advanced
melanoma. Interest has, therefore, turned to earlier diagnosis
and prevention. However, biomarkers suitable for targeting
on prevention remain elusive. IFNa is the only Food and
Drug Administration (FDA)-approved adjuvant therapy of
melanoma. All trials of high-dose IFNa (HDI) have demon-
strated significant reduction in relapse frequency, and two
independent multicenter trials of this regimen have also
demonstrated significant prolongation of survival (Kirkwood
et al., 1996, 2000, 2001, 2004). In this setting, IFNa was
evaluated as a probe in relation to biomarkers of progression
in melanoma.
Clinically atypical and histopathologically dysplastic nevi
have been demonstrated to be nonobligate precursors and
biomarkers of melanoma risk, as reviewed by Hussein (2005).
The effects of IFNa on these lesions have not been
documented, nor have reliable biomarkers of melanoma risk
been identified. This study has evaluated the effects of IFNa
on markers of progression in atypical (dysplastic) melanocytic
nevi to examine the clinical and pathological effects of
modulation of the signal transducer and activator of
transcription (STAT)1 and STAT3 signaling pathways. In
previous studies, it has been demonstrated that the STAT1
and STAT3 signaling pathways are closely related to the
impact of HDI upon metastatic melanoma (Wang et al.,
2007). STAT3 has been shown to be constitutively activated
in melanoma, and the pSTAT1tyr701 (pSTAT1)/pSTAT3-
tyr705 (pSTAT3) ratio has been evaluated as a potential
prognostic index, with higher pSTAT1/pSTAT3 ratios in
tumor tissue predicting improved overall survival of patients
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(Wang et al., 2007). IFNa upregulates the pSTAT1/pSTAT3
ratio (Wang et al., 2007). Therefore, the balance of pSTAT1
and pSTAT3 was evaluated as an index of melanoma
progression.
The JAK/STAT signaling pathway of type I IFN action is
associated with cell growth, differentiation, and immuno-
regulation as reviewed recently by Schindler et al. (2007).
STAT1 is a tumor suppressor important for growth restraint as
well as a regulator of host tumor immune response that
mediates effects of IFNa in murine models. STAT3 is a
mediator of neoplastic progression. STAT3-induced immu-
nosuppression is an important component of melanoma
progression. The relevance of changes in STAT1 and STAT3
signaling was therefore evaluated in the context of two
prospective IFNa trials (HDI and low-dose IFNa (LDI))
focusing on patients with multiple (44) clinically atypical
nevi and a history of prior cutaneous melanoma as depicted
in Figure 1. We report that pSTAT3 is a potential biomarker of
melanoma risk and that STAT signaling is regulated in a dose-
dependant manner by IFNa in vivo.
RESULTS
Baseline level of pSTAT3 expression is positively associated with
the degree of histological atypia of nevi
One hundred and sixty-eight nevi obtained from 42 patients
were studied. Thirty-two patients were evaluated from UPCI
96-043 and 10 patients were recruited from UPCI 95-071.
First, it was noted that with maturation of melanocytes from
the uppermost junctional elements to the deepest dermal
elements, there was progressively diminished expression of
pSTAT3 (denoted in red), whereas the expression level of
pSTAT1 (denoted in blue) was observed to increase, as shown
in Figure 2. Figure 2a was taken using a  10 objective,
whereas Figure 2b was the amplification of the outer
junctional melanocytes and Figure 2c was the amplification
of the deeper dermal melanocytes. In Figure 2, the level of
pSTAT3 expression is higher in junctional melanocytes than
in dermal melanocytes, both in regard to intensity and
percentage of positive cells, whereas pSTAT1 expression
level is higher in dermal melanocytes than that in junctional
melanocytes. The baseline percentages of melanocytes
expressing pSTAT1 or pSTAT3 are shown in Table 1. The
percentages of melanocytes positive for pSTAT1 or pSTAT3
are different (pSTAT1: Po0.0001; pSTAT3: P¼0.011)
between junctional (pSTAT1: 6.18±1.2; pSTAT3:
37.74±3.66) and dermal (pSTAT1: 24.79±3.22; pSTAT3:
28.93±3.3) compartments. The pSTAT1/pSTAT3 ratios are
different (Po0.0001) between junctional (0.36±0.16) and
dermal (2.71±1.50) compartments. We further describe the
pattern of pSTAT1 and pSTAT3 expression among nonatypical
a b
c d
Figure 1. Photographic documentation for the study of multiple nevi.
Patients with multiple nevi larger than 4mm diameter and a history of primary
cutaneous melanoma are eligible for two separate studies. Four nevus lesions
(a–d) were selected randomly for study. Two of them were chosen randomly
to be resected before LDI or HDI treatment. The remaining two nevi were
resected post-LDI or HDI therapy.
a
b c
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Figure 2. The pattern of expression of pSTAT1 and pSTAT3 in nevus. The
baseline expression levels of pSTAT1 and pSTAT3 were observed in this
prospective study. With the maturing of melanocytes from the epidermal
junction to the deep dermis, the expression of pSTAT3 (red chromogen)
was decreased, whereas the expression of pSTAT1 (blue chromogen) was
increased. (a) Taken by  10 objective. (b) The amplification of junctional
melanocytes and (c) the amplification of dermal melanocytes. The pSTAT3
expression level is higher in junctional melanocytes than that in deep dermal
melanocytes, whereas pSTAT1 expression level is higher in deep dermal
melanocytes than that in junctional melanocytes.
Table 1. pSTAT1 and pSTAT3 of junctional and dermal
melanocytes
Biomarkers Melanocyte n Mean SE P-value
pSTAT1 Junctional 34 6.18 1.2 o0.0001
Dermal 34 24.79 3.22
pSTAT3 Junctional 34 37.74 3.66 0.011
Dermal 34 28.93 3.3
pSTAT1/pSTAT3 Junctional 33 0.36 0.16 o0.0001
Dermal 33 2.71 1.5
n, number of patients; pSTAT, phosphorylated signal transducer and
activator of transcription.
Data are presented as mean±SE. Po0.05 is considered significant.
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nevi, atypical nevi, as well as in primary melanoma (three
cases) and metastatic melanoma with regional lymph node
involvement. The pattern of our observation is that the
baseline expression levels of pSTAT3 increased progressively
for lesions that lie in the sequence of progression from benign
melanocytes, atypical melanocytes, primary melanoma cells,
and up to metastatic melanoma cells of regional lymph
nodes, both in terms of intensity and percentage of positive
cells. However, melanoma cells metastatic to regional lymph
nodes exhibited both high levels of pSTAT1 and pSTAT3.
We analyzed the correlation between pSTAT3 expression
and the severity of histopathological atypia and architectural
disorder in the atypical nevi sampled in this prospective trial.
We assessed the severity of histopathological atypia from the
formal pathology reports, using a formal synoptic algorithm
that has been in place for more than a decade in the UPCI
Melanoma and Skin Cancer Program. According to the
cytomorphology, atypical nevi were grouped into three
categories (Arumi-Uria et al., 2003; Shapiro et al., 2004;
Elder, 2006): mild atypia (melanocytes are slightly larger than
adjacent keratinocytes, with small nucleoli); moderate atypia
(junctional melanocytes increased slightly in amount of
cytoplasm with larger nucleoli and have two or more
junctional nests); and severe atypia (large melanocytes with
abundant cytoplasm, 1.5–2 times the size of adjacent
keratinocytes, with large nucleoli, and lentiginous prolifera-
tion at the shoulder or between nests). Data analysis used
Spearman’s rank correlation coefficient ‘‘r’’ to demonstrate
that the baseline percentage of pSTAT3-positive melanocytes
is positively associated with the degree of atypia judged
formally and recorded in the pathology reports for the
sampled lesions (Figure 3, n¼ 57, r¼ 0.50, Po0.0001). In
Figure 3, a score of atypia¼0 signifies no evidence of atypia;
a score¼1 signifies mild atypia; a score X2 signifies
moderate or more severe atypia. Wilcoxon rank sum tests
further demonstrated that the percentage of pSTAT3-positive
melanocytes was significantly different in terms of no atypia
(19.58±5.13, n¼ 12) versus mild atypia (40.29±3.93,
n¼38, P¼0.0090), mild atypia versus moderate atypia
(67.86±9.12, n¼ 7, P¼0.0096), and no atypia versus atypia
(44.58±3.87, n¼ 45, P¼ 0.0024). The original data relating
to baseline levels of junctional pSTAT1 and pSTAT3, the
grade of atypia, and the thickness of the primary melanoma
are listed in Table 1 of the Appendix.
LDI and HDI downregulate pSTAT3tyr705 and upregulate
pSTAT1tyr701 and the pSTAT1/pSTAT3 ratio in
nevomelanocytic lesions dose-dependently
On the basis of the above observations, pSTAT1 and pSTAT3
were considered as potential biomarkers of nevomelanocytic
progression. As HDI is the only approved adjuvant therapy
for high-risk melanoma (Kirkwood et al., 1996, 1999, 2001,
2004; Kirkwood and Tarhini, 2003), we asked what effect this
therapy had on the potential biomarkers of progression in
dysplastic nevi. IFNa2b was selected as a positive control and
reference point for the evaluation of the impact of alternative
regimens of potential utility, to assess changes in the
marker(s) that may correlate with clinical outcome in
potential precursors, such as atypical nevi. We analyzed
the effects of LDI (28 cases) and HDI (8 cases) on pSTAT1 and
pSTAT3 in atypical melanocytic lesions, as these lesions are
currently the best understood histopathologic risk markers
of melanoma and represent nonobligate precursor lesions.
As shown in Table 2, junctional melanocytes demonstrated
downregulation of the percentage of pSTAT3-positive melano-
cytes before (40.91±4.19%) and after (26.00±3.07%,
P¼0.0003) treatment with LDI. The corresponding distribu-
tions of the percentage of pSTAT3-positive melanocytes
before and after HDI were observed to be 40.31±4.94%
and 18.13±2.83% (P¼0.008), respectively. The percentage
of pSTAT1-positive melanocytes measured in biopsy samples
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Figure 3. The expression of pSTAT3 is positively associated with the
severity of atypia. The baseline expression level of pSTAT3 is positively
associated with the degree of atypia in nevi, n¼57, r¼ 0.50, Po0.0001.
Zero represents no atypia (n¼ 12); 1, mild atypia (n¼ 38); and 2, moderate
atypia (n¼ 7). The bar inside the box represents the median.
Table 2. pSTAT1 and pSTAT3 of junctional
melanocytes
IFNa2b Biomarker Time point n Mean SE P-value
High-dose STAT1 Pre 8 2.88 0.99 0.016
Post 8 25.06 9.88
STAT3 Pre 8 40.31 4.94 0.008
Post 8 18.13 2.83
STAT1/STAT3 Pre 8 0.073 0.03 0.008
Post 8 1.51 0.6
Low-dose STAT1 Pre 28 6.04 1.25 0.0059
Post 28 12.27 2.23
STAT3 Pre 28 40.91 4.19 0.0003
Post 28 26 3.07
STAT1/STAT3 Pre 27 0.24 0.08 0.004
Post 27 0.71 0.19
n, number of patients; STAT, signal transducer and activator of
transcription.
Data are presented as mean±SE. Po0.05 is considered significant.
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of atypical nevi was found to be upregulated from pretreat-
ment values of 6.04±1.25% rising to 12.27±2.23%
(P¼0.0059) with LDI, and from 2.88±0.99% rising to
25.06±9.88% (P¼0.016) with HDI. The pSTAT1/pSTAT3
ratio was upregulated from a baseline value of 0.24±0.08 to
0.71±0.19 (P¼ 0.0040) with LDI, and from 0.073±0.03 to
1.51±0.60 (P¼ 0.008) with HDI, respectively. Table 3
demonstrates changes in pSTAT3, which is downregulated
36% from baseline with LDI and 55% from baseline with
HDI. Conversely, pSTAT1 expression was found to be
upregulated by LDI (100%) and HDI (770%) over baseline.
The ratio of pSTAT1/pSTAT3 was upregulated 2- and 20-fold
from baseline ratios by LDI and HDI, respectively. Figure 4
demonstrates that the regulation of STAT signaling by IFNa is
strongly dose-dependent. Figure 4a and b represent pre- and
post-treatment images from subjects receiving LDI illustrating
that LDI downregulates pSTAT3 and upregulates pSTAT1
significantly. Figure 4c and d represent pre- and post-
treatment images obtained from subjects receiving HDI,
showing downregulation of pSTAT3 and upregulation of
pSTAT1 by HDI exceeding that observed with LDI.
DISCUSSION
A defect in the IFNa promoter observed in early melanoma
supports the consideration of IFN signaling as one component
of the etiology of melanoma (Price et al., 2005). A range of
treatment regimens with IFN at various dosages has been
explored for therapy of melanoma in multiple trials con-
ducted worldwide over the past 20 years. At low dosages,
IFNa2a delays recurrence of intermediate-risk melanoma
patients (Grob et al., 1998). At high dosages, we have
previously demonstrated improvement in both relapse-free
and overall survival of patients assessed at median intervals
ranging from 2 to more than 16 years of follow-up (Kirkwood
et al., 1996, 2001, 2002). This study evaluated the effects of
LDI and HDI on pSTAT1tyr701 and on the ratio of pSTAT1/
pSTAT3 expression in nevi and demonstrated augmentation
of both of these parameters as well as downregulation of
pSTAT3tyr705 expression in the atypical nevi of melanoma
patients who participated in the two clinical trials of
IFNa evaluated here. This study provides data that are
consistent with the results obtained in earlier biopsy studies
of lymph node metastases we have conducted in the
neoadjuvant setting (trial UPCI 00-008) (Moschos et al.,
2005; Wang et al., 2007). This study documents the dose-
dependent modulation of STAT signaling molecules in
atypical/dysplastic melanocytic nevi of patients with mela-
noma. Analysis of dose–response effects have demonstrated
greater magnitude of STAT modulation by HDI than LDI, with
effects on pSTAT1, pSTAT3, and the pSTAT1/pSTAT3
ratio that are consistent with the results of clinical trials that
have explored these regimens in the adjuvant therapy of
intermediate- and high-risk melanoma, as already discussed.
The impact of IFNa on the STAT1/STAT3 signaling pathways
appears to predict the clinical outcome of patients treated in
this series.
It has been documented by others that the antitumor
effects of IFNa are abrogated in STAT1-deficient knockout
mice (Lesinski et al., 2003). Deficient IFN-induced STAT1
phosphorylation in vitro and in vivo has also been associated
with melanoma (Kovarik et al., 2003). Most recently, it has
been demonstrated that deficient STAT1 phosphorylation in
T cells of patients with melanoma can be corrected by
exposure to high, but not low, concentrations of IFNa
(Critchley-Thorne et al., 2007). Those previous studies
support the conclusion drawn from these data that IFN-
mediated upregulation of pSTAT1 is important in relation to
the effects of IFNa on melanoma and its precursors.
Upregulation of pSTAT1 in melanoma cells associated with
the antimelanoma effects of IFN has been documented
in vitro (Gollob et al., 2005). With melanocyte maturation
from the dermoepidermal junction to the deeper dermis, we
have observed that expression of pSTAT1 increases, whereas
expression of pSTAT3 decreases. This observation is con-
sistent with the previous studies, suggesting that pSTAT1 is
associated with growth restraint and antagonizes the effects
of STAT3 (Schindler et al., 2007). We have noted that
expression of pSTAT1 in metastatic tumor cells of regional
lymph nodes is much higher than that in nevi and primary
melanoma. We hypothesize that the host immune factors in
Table 3. The fold of post-treatment pSTAT1 and
pSTAT3 against baseline
Fold against baseline
pSTAT1 pSTAT3 pSTAT1/pSTAT3
High-dose IFNa2b 7.7 0.55 20.0
Low-dose IFNa2b 1.0 0.36 2.0
pSTAT, phosphorylated signal transducer and activator of transcription.
Data are presented as (post-treatment mean – pretreatment mean)/
pretreatment mean.
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Figure 4. pSTAT1 and pSTAT3 immunohistochemistry of nevi. (a and b) The
pre- and post-treatment with LDI, show that LDI downregulates pSTAT3 (red
color) and upregulates pSTAT1 (blue color). (c and d) The pre- and post-
treatment with HDI, show that HDI downregulates pSTAT3 (red color) and
upregulates pSTAT1 (blue color) to a greater extent than LDI.
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the lymph node lead to upregulation of pSTAT1 in melanoma
cells and restraint of melanoma proliferation.
Constitutive expression of STAT3 is associated with
melanoma and other solid tumors, and STAT3 has therefore
been evaluated here in the melanocytes of clinically atypical
and histopathologically dysplastic nevi. The role of STAT3 as
a biomarker of progression has been evaluated in two
prospective studies in which the impact of IFNa was
evaluated at low or high dosages. The degree of pSTAT3
expression has been shown to be associated with the degree
of severity of melanocytic atypia judged pathologically, and
IFNa has been shown to downregulate pSTAT3 expression in
the junctional melanocytes of atypical nevi, much as we have
previously documented that it modulates STAT3 expression
in regional nodal metastases of melanoma. It has been
documented that activated pSTAT3 is a potential biomarker
of cancer progression (Huang, 2007). STAT3 and micro-
phthalmia-associated transcription factor cooperatively
induce c-fos, resulting in cellular transformation in vitro
(Joo et al., 2004). STAT3 is a pivotal transcription factor in the
regulation of cell motility and tumor progression (Gao and
Bromberg, 2006; Yang et al., 2006). STAT3 signaling, along
with mitogen-activated protein kinase signaling, appear to
be essential for immune evasion by human melanoma
(Sumimoto et al., 2006). We conclude that pSTAT3 is a
promising biomarker of melanocytic progression, is asso-
ciated with the histopathological dysplasia of melanocytic
nevi, and merits further evaluation as a biomarker of
melanoma progression in prospective adjuvant therapy trials
as well as in prevention trials.
MATERIALS AND METHODS
Surgical specimens and patient treatment
Institutional review board-approved clinical protocols UPCI 96-043
and UPCI 95-071 were the basis of this study. Patients (42) with
multiple (X4) nevi of a diameter X4mm and a history of primary
cutaneous melanoma were eligible for these studies. Patients (32)
with low or intermediate risk of relapse (defined as a melanoma of
less than stage IIB or III) were candidates for UPCI 96-043. The
protocols of the Declaration of Helsinki Principles were followed,
and all of the participating patients of the described research
provided written informed consent. After providing written informed
consent and having clinical photographic documentation, baseline
biopsies were obtained during the course of this study; patients then
received low-dose IFNa2a (LDI) therapy for 12 weeks. Patients (10)
with a high-risk melanoma (defined as a melanoma of stage IIB or III)
were candidates for UPCI 95-071, and following similar informed
consent, these patients had clinical, photographic, and biopsy
documentation and received high-dose IFNa2b as standard adjuvant
therapy (HDI). Treatment with LDI used IFNa2a provided by
Hoffmann La-Roche Pharmaceuticals (Nutley, NJ) (Roferon A),
administered at a dosage of 3 106U subcutaneously three times
weekly for 12 weeks. Treatment with HDI used IFNa2b obtained
commercially and was administered according to the FDA-approved
E1684 regimen in which treatment was given intravenously daily for
5 days per week for 4 weeks at 20 106Um2, followed by
treatment given subcutaneously at 10 106Um2 three times per
week for 48 weeks. Each patient was examined by members of the
dermatology and/or medical oncology faculty of the Melanoma and
Skin Cancer Program of the UPCI and by allied health professionals
in the Melanoma and Skin Cancer Program who have expertise in
the clinical assessment of nevocellular nevi. Lesions were scored by
consensus to select the four most atypical nevi of a diameter
exceeding 4mm in each participant. Nevi were then marked and
denoted alphabetically A–D in descending order of clinical atypia,
and photographically documented. The four nevi selected as the
most atypical were required not to exhibit features that were
regarded as suspicious of overt melanoma, and they were then
assigned a random order for biopsy under the direction of the study
statistician, through the Office of Clinical Research of the Melanoma
and Skin Cancer Program. For assignment of biopsy order, a table of
random numbers provided by the study statistician was used. The
photographic documentation for this study is shown in Figure 1. Two
atypical nevi chosen in this manner at random were scheduled for
excisional biopsy performed before initiation of any treatment with
LDI or HDI. The remaining two nevi were followed photographically
through the course of 3 months of treatment at monthly intervals and
resected post-treatment with LDI or at the third month of treatment
with HDI. Nevi (168) were evaluated initially and prosected by the
dermatopathologist prior to any research laboratory procedures.
A portion of the biopsies was evaluated to confirm the diagnosis, and
a portion of the remaining sample was then released by the
Pathology Department for use in research purposes described in
protocols UPCI 96-043 and UPCI 95-071.
Immunohistochemistry
Rabbit polyclonal anti-human pSTAT1tyr701 and anti-human
pSTAT3tyr705 were purchased from Cell Signaling Technology
(Beverly, MA). Unconjugated goat anti-rabbit IgG (Hþ L) antibody,
which is used to block the first primary antibody in the double
immunostain, was purchased from Vector Laboratories (Burlingame,
CA).
Snap-frozen tissues were fixed in ice-cold acetone for 10minutes.
Indirect immunohistochemistry was performed to detect the specific
antigens of concern with Vector Laboratories’ Vectastain ABC
System (alkaline phosphatase system), and double immunostains
were performed according to the manufacturer’s instructions.
Data analysis and statistics
The  20 objective was used to evaluate the whole section by two
pathologists who were blinded in regard to treatment assignment.
Quantitation was decided by consensus of the two pathologists and a
research faculty member. The percentage of cells with positive
staining was evaluated for all samples. Cells with staining intensity
1þ to 4þ were considered positive; cells without staining (intensity
0) were considered negative. If the percentage of stained cells was
less than 1%, it was considered zero. Statistical analysis was
performed by the UPCI Biostatistical Facility. Mean values of the
percentage of positive cells were presented with SE. Comparisons
between pre- and post-therapy samples were performed with
Wilcoxon signed rank tests, in terms of the fraction of cells
expressing the biomarkers studied and the ratios calculated.
Wilcoxon rank sum tests were used to compare the percentage of
cells expressing the biomarkers between different atypical degrees of
nevi in the pretreatment biopsies. Spearman’s rank correlation
coefficients were computed to analyze the correlation between the
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grades of atypia and the percentage of positive staining cells.
Two-sided P-values were calculated and Po0.05 was considered
significant.
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